The Pipeline

Proof of Concept to Broad Clinical Validation & Regulatory Approval

  • PBM pipeline is pioneering the path towards Precision Diagnosis of Occult Metastasis in patients with most prevalent malignancies.
  • Metastases are still the main cause of cancer-related mortality.
  • Our vision is to develop early screening laboratory technologies to predict occult liver and brain metastasis, for better supporting anti-metastatic therapy anticipation prior to open metastasis development.

Occult Breast Cancer Brain Metastasis

  • Ten to 20% patients with breast cancer develop brain metastases.
  • An additional 35% have detectable brain metastasis at autopsy, suggesting that breast cancer may involve woman’s brain in around 40-50% patients.
  • While brain metastasis incidence is increasing and its detection at its earliest stage is needed, there is no consensus on how to screen for intracranial micrometastases.
  • Imaging (CT and advanced MRI techniques) cannot detect micrometastasis and new methods are needed.
  • PBM scientists verified that BC cells use the perivascular space of cerebral small vessels as a conduit for tumor invasion and proliferation, which in turn leads to a subclinical cerebrovascular reaction of potential interest for diagnosis
  • Next, with the help of LLC-MS/MS proteomics PBM scientists have identified a panel of soluble proteins from tumor-activated blood brain barrier-forming cerebrovascular cells.
  • Now, PBM is validating a brain metastasis-specific identifier biomarker panel that will precede the development and commercialization of a multiplex antibody microarray for the early screening of women at risk of brain metastases.
  • This technology may help to support anti-metastatic therapy anticipation prior to open brain metastasis development in patients with BC but also with other malignancies at risk of brain metastasis recurrence such as lung cancer and melanoma.

Occult Colorectal Cancer Liver Metastasis

  • The liver is one of the most commonly involved body sites for metastasis, both in adult and child malignancies.
  • Its hepatic predisposition to metastatic recurrence is differently regulated in each patient by its genetic background and the liver-stimulating effects of soluble factors delivered from remote primary tumors.

  • PBM scientists have discovered that a hepatic metastasis propensity enhancement develops prior to primary colorectal cancer removal and can be detected in liver biopsies and blood samples obtained during colorectal cancer surgery.
  • PBM scientists are now developing a laboratory test to determine the liver prometastatic reaction in hepatic biopsies (gene expression array) and in the blood (multiplex antibody microarray) from colorectal cancer patients without clinically-detectable metastases.
  • These tests may help prognosticating, monitoring and even preventing hepatic metastasis recurrence in patients with resected gastrointestinal malignant tumors, but also with non-gastrointestinal malignancies at risk of hepatic metastasis recurrence such as lung, adrenal, prostate and breast cancers, melanoma and sarcoma.
  • They may also be helpful for predicting time to recurrence and post-recurrence survival in patients who undergo primary curative hepatectomy for the resection of colorectal cancer metastases; and may help patients with invasive colorectal cancer whose hepatic metastases are not detectable by imaging.
  • Positive results may suggest upstaging of the colorectal cancer according to conventional staging system, allowing physicians to decide on administration of neoadjuvant therapy or prophylactic adjuvant hepatic arterial infusion chemotherapy for prevention of hepatic metastasis development.